77 A Radio Opaque Suture May Improve Radiation Target Delineation in Post Lumpectomy Patients With Breast Cancer: A Retrospective Analysis

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4
Pages: 57

77 A Radio Opaque Suture May Improve Radiation Target Delineation in Post Lumpectomy Patients With Breast Cancer: A Retrospective Analysis

77 A Radio Opaque Suture May Improve Radiation Target Delineation in Post Lumpectomy Patients With Breast Cancer: A Retrospective Analysis

Background/Significance

The identification of the tumor bed following lumpectomy is vital for successful radiation treatment, both for a breast radiation boost and more fundamentally in the partial breast setting. However, identification of the tumor cavity on a planning CT scan can be complicated as postsurgical seromas will inversely decrease with time and preoperative imaging may not anatomically correlate. In addition, the radiation target should correlate with the tumor pathology size. VeraForm is a radio-opaque continuous multiplane marker that is sutured into the operative bed during the lumpectomy. The aim of this study is to compare VeraForm markers (VF), surgical clip (SC) placement, and no clips (NC) on target delineation in relation to the tumor bed.

Materials and Methods

Beginning in July 2023, a single breast surgeon placed VF in lumpectomy. We retrospectively reviewed 48 women, 19 women with VF and compared with 13 women with SC and 24 women with NC. The tumor volume was calculated by taking the surgical specimen 3-dimensional measurements and multiplying it by π/6. We created a ratio between the specimen and the CTV (radiation target volume of the tumor bed, which was created by a board certified radiation oncologist). We then used a 2 sample Welch t-test to compare 3 populations.

Results

The population was mainly T0 (28%) and T1 (58%). The treatment was whole breast with a cavity boost in 57% and partial breast in 43%. The medium weight of the patients between VF, SC, and NC was similar (169 lbs, 174 lbs, 169 lbs, respectively), and the time from surgery to radiation mapping was similar (33 days, 40 days, 42 days, respectively). The tumor volume for VF, SC, and NC was 40 mL, 47 mL, and 54 mL, respectively (P = not specified). However, the VF ratio to tumor volume had less variance than NC (P = .0436) but showed no improvement over the SC (P = .289). SC did not show an improvement over NC (P = .239).

Conclusion

In this single-institution retrospective study, VF led to a target volume that was more consistent with the tumor specimen size than no markers. However, it did not yield an improvement over SC placement.

Articles in this issue

3 Intraoperative Radiotherapy: Alive and Well in the Bronx
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast
20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast
Recent Videos
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.